But the price of these injections is steep: They cost about $800-$1,000 per month, and if used for weight loss alone, they are not covered by most insurance policies. Both drugs mimic the naturally occurring hormone GLP-1 to help regulate blood sugar and reduce cravings. They can be taken only with a prescription.
The Food and Drug Administration (FDA) announced an official shortage of the active ingredients in these drugs in 2022, but on Oct. 2, 2024, the agency announced that the shortage has been resolved for the medicine tirzepatide, the active ingredient in Mounjaro and Zepbound.
Despite the soaring demand and limited supply of these drugs, there are no generic versions available. This is because the patents for semaglutide - the active ingredient in Ozempic and Wegovy, which is still in shortage - and tirzepatide don't expire until 2033 and 2036, respectively.